glp-1 receptor agonist medication diabetes medications linked to reduced dementia risk TrimRX | GLP-1 vs GIP:

Supplementary Information 40168_2025_2252_MOESM1_ESM.docx (download DOCX Supplementary Material 1: Figure S1

Consider: Escalating to next dose tier Evaluating adherence and lifestyle factors Checking for medication-interfering conditions (hypothyroidism, PCOS, sleep apnea) Discussing alternative treatments Dose-response comparison table: Wegovy vs Zepbound Data from STEP 1 (Wilding et al., NEJM 2021) and SURMOUNT-1 (Jastreboff et al., NEJM 2022)

CoQ10 has a favorable safety and tolerability profile at recommended dosages (typically around 100 mg/day), with studies indicating no significant adverse effects even following prolonged exposure to doses as high as 900 mg/day (171)

In vivo assessment of -cell glucose sensitivity using a graded insulin infusion protocol